| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
69,020,000 |
| Market
Cap: |
106.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6003 - $3.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
94,704 |
7,518,862 |
| Total Buy Value |
$0 |
$0 |
$64,854 |
$66,954,067 |
| Total People Bought |
0 |
0 |
4 |
5 |
| Total Buy Transactions |
0 |
0 |
10 |
94 |
| Total Shares Sold |
0 |
0 |
0 |
85,082 |
| Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Svennilson Peter |
Director |
– • • |
2019-05-07 |
4 |
B |
$14.10 |
$803,700 |
I/I |
57,000 |
15,501,091 |
2.25 |
- |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2019-05-07 |
4 |
B |
$14.10 |
$803,700 |
D/D |
57,000 |
1,932,000 |
2.45 |
- |
|
| Svennilson Peter |
Director |
– • • |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
13,093,134 |
15,444,091 |
|
- |
|
| Svennilson Peter |
Director |
– • • |
2019-04-08 |
4 |
B |
$16.00 |
$30,000,000 |
I/I |
1,875,000 |
2,350,957 |
2.25 |
- |
|
| Svennilson Peter |
Director |
– • • |
2019-04-08 |
4 |
B |
$16.00 |
$320,000 |
D/D |
20,000 |
20,000 |
3.92 |
- |
|
| Goeddel David V |
Director |
– • • |
2019-04-08 |
4 |
B |
$16.00 |
$30,000,000 |
I/I |
1,875,000 |
15,634,091 |
2.25 |
- |
|
| Goeddel David V |
Director |
– • • |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
13,283,134 |
13,759,091 |
|
- |
|
| Schnell David |
Director |
– • – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
4,925,000 |
4,925,000 |
|
- |
|
| Leschly Mark |
Director |
– • – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
3,766,667 |
3,766,667 |
|
- |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2019-04-08 |
4 |
B |
$16.00 |
$30,240,000 |
D/D |
1,890,000 |
15,000 |
2.45 |
- |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
D/D |
13,093,134 |
13,569,091 |
|
- |
|
| Hooper Suzanne Sawochka |
Director |
– • – |
2019-04-08 |
4 |
B |
$16.00 |
$112,000 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
| Tichenor Mchenry T |
Director |
– • – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
1,833,332 |
1,872,314 |
|
- |
|
| Rieflin William Jl |
Executive Chairman |
• • – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
56,668 |
2,769,168 |
|
- |
|
| Kutzkey Tim |
10% Owner |
– – • |
2019-04-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,890,000 |
|
- |
|
| Merck Sharp & Dohme Corp. |
10% Owner |
– – • |
2019-04-08 |
4 |
B |
$16.00 |
$65,946,928 |
I/I |
4,121,683 |
12,955,016 |
1.5 |
- |
|
| Merck Sharp & Dohme Corp. |
10% Owner |
– – • |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
8,833,333 |
8,833,333 |
|
- |
|
| Chen Jin-Long |
Chief Scientific OfficerOffice |
• • – |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
924,943 |
|
- |
|
| Tichenor Mchenry T |
Director |
– • – |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,982 |
|
- |
|
| Column Group Ii Gp, Lp |
10% Owner |
– – • |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
475,957 |
|
- |
|
| Rieflin William Jl |
Executive ChairmanOfficer |
• • – |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,712,500 |
|
- |
|
| Woodhouse David J |
CEO and acting CFOOfficer |
• • – |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
80,000 |
|
- |
|
| Svennilson Peter |
Director |
– • • |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
475,957 |
|
- |
|
| Goeddel David V |
Director |
– • • |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
475,957 |
|
- |
|
499 Records found
|
|
Page 20 of 20 |
|
|
